<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842023</url>
  </required_header>
  <id_info>
    <org_study_id>ACCP-26060</org_study_id>
    <nct_id>NCT00842023</nct_id>
  </id_info>
  <brief_title>Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy</brief_title>
  <acronym>ABC-HFT</acronym>
  <official_title>A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Nesiritide is more effective than
      nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity
      when proper infusion duration is administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No additional details provided
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function by Serum Creatinine</measure>
    <time_frame>Baseline, 24 hours, 48 hours</time_frame>
    <description>Serum creatinine values and changes in serum creatinine</description>
  </primary_outcome>
  <other_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>48 hours</time_frame>
    <description>Interleukin-6</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Levels of Cystatin-C</measure>
    <time_frame>Baseline, 24 hours, 48 hours</time_frame>
    <description>Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Nesiritide Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroglycerin Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide</intervention_name>
    <description>Bolus 2 mcg/kg followed by 0.01 mcg/kg/min</description>
    <arm_group_label>Nesiritide Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>5-10 mcg/min titrating per protocol based on blood pressure</description>
    <arm_group_label>Nitroglycerin Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Subject must be able to understand the potential risks and benefits associated with
             the study.

          -  Baseline systolic blood pressure â‰¥ 90 mm Hg at the time of enrollment.

          -  Clinical symptoms of dyspnea and laboratory admission BNP levels &gt; 500 pg/mL.

          -  Neither pregnant or breastfeeding at the time of enrollment.

          -  Authorization of patient's enrollment by patient's medical provider.

        Exclusion Criteria:

          -  &lt;18 years of age

          -  Denies written informed consent

          -  Pregnant or lactating.

          -  Baseline systolic BP &lt; 90 mmHg or cardiogenic shock

          -  No symptoms of congestion or admission BNP &lt; 500 pg/mL

          -  Known allergy to E.coli-derived products, or any history of anaphylactic reactions to
             nesiritide.

          -  Receiving dialysis at the time of enrollment.

          -  Serum creatinine &gt; 2.5 mg/dL at the time of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheryl L. Chow, PharmD, FCCP, BCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University of Heatlh Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centinela Hospital Medical Center</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail. 2011 Mar;17(3):181-7. doi: 10.1016/j.cardfail.2010.10.005. Epub 2010 Dec 3.</citation>
    <PMID>21362524</PMID>
  </results_reference>
  <results_reference>
    <citation>Chow SL, O'Barr SA, Peng J, Chew E, Pak F, Quist R, Patel P, Patterson JH, Heywood JT. Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circ Heart Fail. 2011 Jul;4(4):450-5. doi: 10.1161/CIRCHEARTFAILURE.110.958066. Epub 2011 May 16.</citation>
    <PMID>21576282</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <results_first_submitted>February 3, 2012</results_first_submitted>
  <results_first_submitted_qc>August 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2013</results_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Sheryl Chow</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Natriuretic peptides</keyword>
  <keyword>BNP</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Nitoglycerin</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nesiritide Infusion</title>
          <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Nitroglycerin Infusion</title>
          <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nesiritide Infusion</title>
          <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Nitroglycerin Infusion</title>
          <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="14.1"/>
                    <measurement group_id="B2" value="66.8" spread="17.2"/>
                    <measurement group_id="B3" value="67.7" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Sample size was estimated at 90 patients total; however, 1 patient was enrolled twice. Therefore, only 89 patients were enrolled in the primary study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Function by Serum Creatinine</title>
        <description>Serum creatinine values and changes in serum creatinine</description>
        <time_frame>Baseline, 24 hours, 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nesiritide</title>
            <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Nitroglycerin</title>
            <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function by Serum Creatinine</title>
          <description>Serum creatinine values and changes in serum creatinine</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum creatinine at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum creatinine at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum creatinine at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Inflammatory Markers</title>
        <description>Interleukin-6</description>
        <time_frame>48 hours</time_frame>
        <population>Only participants with available data were assessed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nesiritide Infusion</title>
            <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Nitroglycerin Infusion</title>
            <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers</title>
          <description>Interleukin-6</description>
          <population>Only participants with available data were assessed for this outcome measure.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="7"/>
                    <measurement group_id="O2" value="50" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Levels of Cystatin-C</title>
        <description>Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function.</description>
        <time_frame>Baseline, 24 hours, 48 hours</time_frame>
        <population>Only participants with available data were assessed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nesiritide</title>
            <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Nitroglycerin</title>
            <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Cystatin-C</title>
          <description>Cystatin-C is a protease inhibitor and a sensitive endogenous marker of renal function.</description>
          <population>Only participants with available data were assessed for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cystatin-C at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1332" spread="1308"/>
                    <measurement group_id="O2" value="2026" spread="1814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystatin-C at 24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1475" spread="1291"/>
                    <measurement group_id="O2" value="3108" spread="3761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystatin-C at 48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1449" spread="1298"/>
                    <measurement group_id="O2" value="2739" spread="3369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nesiritide Infusion</title>
          <description>2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.</description>
        </group>
        <group group_id="E2">
          <title>Nitroglycerin Infusion</title>
          <description>10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP&lt;or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Symptomatic Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Assessed at 6 months</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sheryl L. Chow</name_or_title>
      <organization>Western University of Health Sciences</organization>
      <phone>9094695379</phone>
      <email>schow@westernu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

